Ag
Non vérifié

Agenus Inc.

Ce que nous écrivons

BiotechnologieIndustrie pharmaceutiqueMédecine - DiversOncologieSanté
06/11/2026
Événements
Industrie
Hygiène alimentaire
Industrie pharmaceutique
Oncologie
Santé Publique
Troisième âge
Biotechnologie
Médecine - Divers
Science
Vitrines/Shopping
Services Sociaux
Santé
Agenus Reports More Than Half of Patients with Refractory MSS Metastatic Colorectal Cancer Achieved Long-Term Survival Following BOT+BAL Treatment at SITC 2026
1.00
05/11/2026
Marché financier
Oncologie
Santé
Médecine - Divers
Science
Industrie pharmaceutique
Biotechnologie
Agenus Reports Third Quarter 2026 Results, Highlighted by First Marketing Authorizations for BOT+BAL and Global Investigator Support for Phase 3 ROBBIN Study
1.00
02/11/2026
Web et Réseaux Sociaux
Biotechnologie
Industrie pharmaceutique
Santé
Oncologie
Agenus to Participate in Rodman & Renshaw Virtual Fireside Chat
1.00
02/11/2026
Industrie
Oncologie
Santé
Médecine - Divers
Science
Industrie pharmaceutique
Biotechnologie
Agenus Announces Nature Medicine Publication of Multicenter UNICORN Phase 2 Trial Demonstrating Deep Responses with Neoadjuvant BOT+BAL in Resectable Colon Cancer
1.00
25/10/2026
Oncologie
Santé
Médecine - Divers
Science
Industrie pharmaceutique
Biotechnologie
Événements
Industrie
Agenus Reports 72% of Patients with Locally Advanced dMMR Colon Cancer Had No Cancer Remaining at Surgery Following Six Weeks of BOT+BAL in Phase 2 NEOASIS Study at ESMO 2026
1.00
22/10/2026
Biotechnologie
Santé
Industrie pharmaceutique
Médecine - Divers
Oncologie
Finance
Marché financier
Agenus to Provide Third Quarter 2026 Financial Report and Development Update
1.00
09/10/2026
Événements
Web et Réseaux Sociaux
Biotechnologie
Industrie pharmaceutique
Santé
Oncologie
Agenus to Participate in Chardan’s 10th Annual Healthcare Investor Conference
1.00
08/10/2026
Événements
Industrie
Oncologie
Santé
Médecine - Divers
Science
Industrie pharmaceutique
Biotechnologie
Armenia Grants First Marketing Authorizations for Agenus’ BOT+BAL in Previously Treated MSS Metastatic Colorectal Cancer
1.00
03/10/2026
Biotechnologie
Santé
Industrie pharmaceutique
Médecine - Divers
Oncologie
Événements
Industrie
Agenus Reports 48% Estimated Three-Year Survival With BOT+BAL in Recurrent Ovarian Cancer at IGCS 2026
1.00
02/10/2026
Événements
Industrie
Biotechnologie
Santé
Industrie pharmaceutique
Médecine - Divers
Oncologie
Agenus to Present BOT+BAL Long-Term Survival Data and Translational Research With agenT-797 in Colorectal Cancer at SITC 2026
1.00

Détails du contact

Réseaux sociaux

Followers
0
Compatibilité
0